Warwick Grant has spent his professional life researching parasitic diseases in sub-Saharan Africa and has championed the search for affordable treatment of neglected tropical diseases. He sits on the advisory panel for parasitic worm disease for the World Health Organisation. In a world first, the Australian not-for-profit biopharmaceutical company, Medicines Development for Global Health, took over the sponsorship of a novel small molecule, Moxidectin, and prosecuted its case for approval by the FDA.
Their association will change the lives of millions of people.
